
|Videos|November 29, 2022
Episode 11A: Effect of Trilaciclib in Patients Receiving Chemotherapy for ES-SCLC Treatment
Author(s)Paul A. Bunn, MD
Dr Paul Bunn briefly reviews key efficacy data from a pooled analyses of trilaciclib in chemotherapy induced myelosuppression and discusses strategies to manage neutropenia in patients receiving chemotherapy for extensive-stage small cell lung cancer (ES-SCLC).
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5



















































